Trajectories and predictive significance of inflammatory parameters for clinical outcome in COVID–19 patients treated with tocilizumab
CRP-decline and IL-6 increase after tocilizumab treatment occurs regularly. An increase of IL-6 levels exceeding tenfold of baseline IL-6 levels, an absolute peak of 1000 pg/ml or a renewed increase of CRP are associated with higher mortality. Suppressed CRP synthesis can impede the diagnosis of bacterial superinfections, thus increasing the risk for complications.
Authors
- Tom Luedde (ORCID: https://orcid.org/0000-0002-6288-8821)
- Johannes G. Bode (ORCID: https://orcid.org/0000-0002-7141-0694)
- Torsten Feldt
- Charlotte Flasshove
- Clara de Angelis
- Björn‐Erik Ole Jensen (ORCID: https://orcid.org/0000-0003-1626-4855)
- Jörg Timm (ORCID: https://orcid.org/0000-0001-7799-3045)
- Kirsten Alexandra Eberhardt (ORCID: https://orcid.org/0000-0002-1002-0326)
- Nadine Lübke (ORCID: https://orcid.org/0000-0003-3820-7915)
- Noemi F. Freise (ORCID: https://orcid.org/0000-0002-1073-1793)
- Hans Martin Orth (ORCID: https://orcid.org/0000-0003-3053-6730)
- Smaranda Gliga (ORCID: https://orcid.org/0000-0001-8191-504X)
- Alexander Killer (ORCID: https://orcid.org/0009-0004-8427-0266)
- C Ackermann
- Pascal Massion
Institutions
- Universität Hamburg (DE)
- Düsseldorf University Hospital (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Heinrich Heine University Düsseldorf (DE)
- Bernhard Nocht Institute for Tropical Medicine (DE)
Publication Details
- Journal
- Infection
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1007/s15010-024-02375-x
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39